Key facts
- Science Corporation said it raised a $400 million Series D, with investors including Khosla Ventures, Tenet Healthcare and Y Combinator.
- A person familiar with the deal told TechCrunch the round valued the company at $3.5 billion.
- Science's first product, PRIMA, is a wearable and implantable chip that helps people with age-related macular degeneration recover some vision.
- PRIMA is approved in Europe and available in Germany, and is being trialled for new conditions.
- Science aims to bring PRIMA to the US through the FDA's Humanitarian Device Exemption.
- Yale neurosurgery professor Murat Günel told TechCrunch the bio-hybrid sensor could offer potential treatments for Parkinson's disease.
Science Corporation, the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post. A person familiar with the deal told TechCrunch the round valued the company at $3.5 billion. Backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.
Science's first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, and is being trialled for new conditions. Hodak announced at TechCrunch Disrupt that the device is now being trialled for patients with Stargardt's disease, another blindness-causing condition.
With the funding, the company aims to bring the device to the United States through the FDA's Humanitarian Device Exemption, which lets experimental medical technology be used to treat rare conditions. Science has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to let it seek approval to use the device on people in the US.
The start-up's founding purpose is connecting directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. The company is designing initial human trials of the device with Yale neurosurgery professor Murat Günel, who told TechCrunch it could offer potential treatments for Parkinson's disease, among other brain injuries and illnesses.
